Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Balestro (Padova, Italy), D. Biondini (Padova, Italy), C. Rigobello (Padova, Italy), M. Campisi (Padova, Italy), S. Baraldo (Padova, Italy), F. Fracasso (Padova, Italy), G. Foltran (Padova, Italy), E. Cocconcelli (Padova, Italy), G. Castelli (Padova, Italy), E. Bazzan (Padova, Italy), M. Cosio (Montreal, Canada), M. Saetta (Padova, Italy), S. Pavanello (Padova, Italy), P. Spagnolo (Padova, Italy). Association between leukocyte telomere length (LTL) and functional decline in patients with Idiopathic Pulmonary Fibrosis (IPF) on antifibrotic treatment. 1925

Member's Comments

No comment yet.

Related content which might interest you: Association between MUC5B rs35705950 genotype and response to antifibrotic treatment in patients with Idiopathic Pulmonary Fibrosis (IPF). Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis Year: 2020 Lymphocyte to monocyte ratio (LMR) predicts survival in patients with Idiopathic Pulmonary Fibrosis (IPF). Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Effect of 24-month Pirfenidone treatment on functional decline in Idiopathic Pulmonary Fibrosis (IPF) patients with rapid and slow disease progression Source: International Congress 2017 – The wide spectrum of ILDs Year: 2017 Association between AGTTGFB1ESR1, and VDR gene variants with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis (PS) clinical features Source: International Congress 2017 – Functional genomics knowledge in parenchymal and bronchial diseases Year: 2017 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Ca 19-9 serum levels in patients with end-stage Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 The study of telomere associated genes and telomere measurement in Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR) Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation Year: 2020 Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Treatment of idiopathic pulmonary fibrosis (IPF) with pentoxifylline (POF) Source: Eur Respir J 2007; 30: Suppl. 51, 121s Year: 2007 LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 246s Year: 2007 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Combined Pulmonary Fibrosis and Enphysema (CPFE): correlation between TC parameters and functional decline. Source: International Congress 2017 – Various imaging modalities for different lung diseases Year: 2017